Lurbinectedin is a medication that has shown promise in the treatment of cancer. According to Drug Patent Watch [1], the drug was granted orphan drug status by the FDA in 2017 for the treatment of small cell lung cancer (SCLC). It works by inhibiting the transcription of DNA, which prevents the growth and spread of cancer cells.

A study published in the Journal of Clinical Oncology [2] evaluated the effectiveness of lurbinectedin in treating patients with relapsed SCLC. The study found that the drug had a response rate of 35.7% and a disease control rate of 82.1%. The median progression-free survival was 4.2 months, and the median overall survival was 9.3 months. The study concluded that lurbinectedin showed promising activity in patients with relapsed SCLC.

Another study published in Cancer Network [3] evaluated the safety and efficacy of lurbinectedin in combination with pembrolizumab in patients with relapsed SCLC. The study found that the combination was safe and well-tolerated, with a response rate of 60% and a disease control rate of 80%. The median progression-free survival was 5.2 months, and the median overall survival was 9.9 months. The study concluded that the combination of lurbinectedin and pembrolizumab was effective in treating relapsed SCLC.

In summary, the available evidence suggests that lurbinectedin is effective in treating relapsed SCLC, either alone or in combination with other drugs. However, more research is needed to fully understand the drug's potential and to determine its effectiveness in other types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.cancernetwork.com/view/preliminary-results-show-second-line-lurbinectedin-plus-pembrolizumab-safe-effective-in-relapsed-sclc